Loading
Everything in development, the open problems and what is being done about them, the roadmaps, and what changed on this record.
What is in development for Parathyroid carcinoma, drawn from the whole corpus: 0 items. Drugs are grouped by the most advanced trial phase they have reached anywhere; approved treatments sit under standard of care. Technologies are the methods being tested for this cancer, trials are the studies recorded here, and ideas are proposals not yet in a trial.
Nothing recorded in development for this cancer yet.
Preoperative diagnosis: no reliable imaging or biochemical threshold, so many patients have inadequate first surgery.
No effective systemic anticancer therapy for metastatic disease; genomic profiling for actionable alterations and immunotherapy case series are the current approach.
Nothing recorded yet.
Nothing recorded yet.
Also on OnCo: Atlas of advanced disease · How cancer spreads: the metastasis stages.
Rarity precludes randomised trials; international registries are the evidence base.
Nothing recorded yet.
Nothing recorded yet.
Also on OnCo: Find a trial · Expert centres.
Dated changes read from the records linked to this cancer: approvals, regulatory steps, reported trials, guideline versions and milestones. Newest first; no date is inferred.
On EdgeAll 8 changes by month →When this page itself was last checked or edited.
Fifth edition endocrine tumours.
En bloc resection with ipsilateral thyroid lobectomy and removal of adherent tissue, avoiding capsule rupture; re-resection for loco-regional recurrence. (NCCN Category 2A)
Hypercalcaemia in patients with parathyroid carcinoma; secondary hyperparathyroidism on dialysis; primary hyperparathyroidism when surgery is not possible
Including hypercalcaemia of parathyroid carcinoma (FDA).
Shattuck and colleagues, NEJM.